AsepticSure Hospital Disinfection System Achieves EPA Approval For US Market Entry

screen-shot-2016-11-18-at-10-08-25-amSan Francisco, California, November 21, 2016 – Medizone International, Inc. (The Company) (OTCQB: MZEI) is pleased to announce that its unprecedented hospital room disinfection technology, AsepticSure®, has been given a green light for US market entry by the United States Environmental Protection Agency (EPA).

In August, Medizone announced that Cogmedix Inc., the Company’s manufacturing partner, had obtained EPA company and establishment numbers to serve as a manufacturer for the AsepticSure System. Cogmedix already held FDA medical device manufacturing status. That EPA Registration allows Cogmedix to ship AsepticSure systems to hospitals and other users in the United States. Today, we are pleased to announce that EPA has granted a Registration number for the AsepticSure specific hydrogen peroxide catalyst used in the system. The AsepticSure Oxidative Catalyst is EPA approved for use in hospitals, clinics, food industry, sporting venues, and hotels to disinfect hard, non-porous surfaces at a 1.4% concentration.

Following the Christmas holiday period, Medizone anticipates entering into a brief trial/demonstration period in a major US hospital to confirm the disinfection results previously achieved in Canada are easily repeatable.

The Company is very optimistic that EPA approval for US market entry signals a turning point for our commercial development program as we move into 2017.`

This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

 

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 415 331-0202
E: j.pentony@medizoneint.com

For more information, visit:
http://www.medizoneint.com
Email: operations@medizoneint.com

 

 

Medizone International, Manufacturer of AsepticSure, Closes Additional Investment

San Francisco, CA October 27, 2016. Medizone International, Inc. (The Company) (OTCQB: MZEI) manufacturers of the un-paralleled AsepticSure® Hospital Disinfection System, announces its South American distribution partner and investment group GYD S.A. operating in South America under the name BioAsepsisCorp., have completed a second investment of $1 million dollars. In November of 2015 GYD invested an initial $1 million dollars for Medizone stock with a one-year lock up. Warrants were issued for the purchase of additional shares under that agreement. The warrants have now been exercised to complete the second million-dollar investment in the Company by GYD S.A.

GYD currently holds AsepticSure distribution and service rights for Chile where they have recently achieved regulatory approval and are now commencing operations. Additional countries GYD holds rights to and expects to expand service into as regulatory approvals are achieved include Peru, Colombia, Brazil and Argentina.

Argentina is a new addition to the original distribution agreement. GYD also obtained additional warrants to purchase a third one-million dollars of Company stock, restricted under SEC Rule 144. The newly issued warrants may not be exercised prior to January 31, 2017 and have a one-year window to exercise from that date, with an expiration of January 30, 2018. Additional details of the investment may be found in the Company’s filing on SEC Form 8K.

This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 415 331-0202
E: j.pentony@medizoneint.com

For more information, visit:
http://www.medizoneint.com
Email: operations@medizoneint.com

Medizone International, Inc. (OTCQB: MZEI)

4000 Bridgeway, Suite 401
Sausalito, CA 94965

Telephone: 415-331-0303

Email: operations@medizoneint.com

Media and Investor Relations:

John Pentony

Medizone International, Inc.

Telephone: (415) 331-0202

Email: j.pentony@medizoneint.com

Social Media


Twitter:


https://twitter.com/asepticsure

CONTACT:

Medizone International, Inc. (OTCQB: MZEI)
4000 Bridgeway, Suite 401
Sausalito, CA 94965

Telephone: 415-331-0303

Email: operations@medizoneint.com

INVESTOR & MEDIA RELATIONS:

John Pentony
Medizone International, Inc.

Telephone: (415) 331-0202E:

Email: j.pentony@medizoneint.com

SOCIAL MEDIA:

Medizone International on Twitter:

https://twitter.com/asepticsure